On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Novartis will acquire Regulus Therapeutics for up to $1.7B, boosting its kidney drug pipeline with lead candidate farabursen.

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance ...

The company already has a US-approved drug for advanced soft tissue tumours, which may soon gain approval in the European Union. Merck had confirmed advanced discussions with SpringWorks last week.

SpringWorks Therapeutics Secures FDA Approval For Second Cancer Drug The deal will be financed through a combination of available cash and newly issued debt. The acquisition aligns with Merck ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...

SANTA FE, N.M. (AP) — The main cause of Gene Hackman’s death was heart disease, but he was also ... negative for alcohol and intoxicating drugs, but that he had a low concentration of acetone ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other most ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...

Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal. More for You Hottest day of the year forecast with UK weather set for 28°C – but there’s no heatwave ...